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from day 1 until neutrophil engraftment. GVAX was initiated be-
tween day 30 to 45 if there was adequate hematologic recovery
and no grade II-IV acute GVHD. GVAX was administered ID/SC
qwk 3 doses, then q2wks 3 doses. Taper of tacrolimus began after
vaccine completion. Ten patients (6 URD, 4 MRD) have been trans-
planted to date: 8 AML, 2 MDS/RAEB-2. Seven had circulating
myeloblasts at transplant. GVAX was successfully generated for all 10
patients.Median vaccine cell dose was 1.0 107cells (range, 0.4-1.0
107), and median 24-hr GM-CSF secretion by vaccine cells was 7.25
ng/ml/106cells (range1.0-155.9). Only 4 of 10 patients were able to
start vaccination post transplant. Reasons for failure to initiate vacci-
nation included: death before day 30 (1); acute GVHD (2); insufﬁ-
cient count recovery (3). Among those who receivedGVAX, there was
no GVHD or toxicity attributable to vaccination. Focal inﬁltrates of
lymphocytes were observed in skin biopsies of the vaccination sites.
Two of four vaccinated patients are alive: 1 in CR, and 1 in relapse 5
and 6 months post transplant, respectively. Overall, 7 of 10 patients
have relapsed, 6 before day 100. Although results are preliminary
and the high incidence of early relapse has hindered our ability to
initiate vaccination, GVAX appears to be safe for patients with MDS/
AML after NST. Further cytoreduction prior to NST is necessary for
disease control and improve feasibility of GVAX vaccination in this
very high-risk population.
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TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA
(CML) AND IMATINIB FAILURE AFTER DEVELOPING BCR-ABL KINASE
MUTATIONS WITH ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT)
Jabbour, E., Cortes, J., De Lima, M., Andersson, B., Giralt, S.,
Kantarjian, H., Champlin, R. University of Texas/M.D. Anderson
Cancer Center, Houston, TX.
ASCT is curative for many pts with CML, and may be effective
after imatinib failure. Resistance to imatinib is most often associ-
ated with point mutations in the Bcr-Abl kinase domain. The
outcome of pts with Bcr-Abl kinase mutations after ASCT is not
known. We assessed the outcome of ASCT in 9 pts with CML
(chronic phase [CP]  3, accelerated phase [AP]  3, blast phase
[BP] n  3) harboring 8 different protein kinase mutations. P-loop
mutations were detected in 4 (44%) pts; T315I mutation was
detected in 2 pts (one AP and one CP). Seven male and 2 female
pts, median age of 44 years (range, 26-63 years), received their
ASCT between June 2003 and July 2005. At the time of ASCT,
one pt was in major molecular remission (MMR) (BP, Q252H),
one was in major cytogenetic response (CP, T315I), and 2 were in
complete hematologic response (2 BP, Y253H and E281A). Pre-
parative regimen was busulfan  cyclophosphamide in 7 and ﬂu-
darabine  cyclophosphamide in 2 pts. Donor was fully matched
related in 4 (44%) and unrelated in 5 (56%) pts. Source of stem
cells was peripheral blood and bone marrow in 7 and 2 pts,
respectively. Graft-versus-host disease (GVHD) prophylaxis con-
sisted of tacrolimus and mini methotrexate. All patients engrafted;
there was no treatment-related mortality. Chimerism studies at day
30 and 100 post ASCT were available in 7 pts and were 100% of
donor type. Eight pts achieved a complete molecular remission
(CMR); one pt with a T315I mutation achieved a MMR. Two
(22%) pts (Q252H [BP] and T315I [AP]) relapsed after a median
of 7 months; one of them (T315I) died of disease progression. All
the remaining 7 pts were in CMR for a median of 13 months
(range, 3-20 months). We conclude that ASCT remains an im-
portant salvage option for pts who develop resistance to imatinib
through Bcr-Abl mutations. Early introduction of such strategy
may result in better outcome.
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IN VIVO BIOLUMINESCENCE IMAGING OF ACUTE PROMYELOCYTIC
LEUKEMIA CELL TRAFFICKING AND MOBILIZATION BY AMD3100
Nervi, B.1, Holt, M.1, Rettig, M.P.1, Bridger, G.2, Ley, T.J.1,
DiPersio, J.F.1 1Washington University School of Medicine, St. Louis,
MO; 2AnorMed, Inc., Langley, BC, Canada.
Novel approaches have been developed to mobilize hematopoi-
etic stem cells (HSC) for patients undergoing autologous and allo
transplantation. These strategies may provide insights into im-
proved HSC collection and enhanced egress of leukemic cells and
thus sensitivity to anti-leukemia therapy. CXCR4/SDF-1 axis reg-
ulates the trafﬁcking of normal HSC to and from the bone marrow
(BM). AMD3100 (AMD) speciﬁcally and reversibly blocks SDF-1
binding to CXCR4, and is a promising mobilizing agent currently
in clinical development. We utilized a mouse model of acute
promyelocytic leukemia in which the PML-RAR
 transgene was
knocked into a single allele of the murine cathepsin G locus. We
transduced banked leukemia cells with a dual function reporter
gene that encodes a click beetle red (CBR) luciferase, a biolumi-
nescence imaging (BLI) optical reporter gene, and EGFP for ex
vivo cell sorting (CBR/EGFP). We isolated EGFP cells using a
MoFlo cell sorter, and passaging them in secondary syngeneic
recipients that developed rapidly fatal acute leukemia. Upon intra-
venous (iv) injection of 106 APL cells into syngeneic recipients,
APL rapidly migrated to the BM, with increased BLI signal in the
femurs, spine, ribs, and skull, at 4 days after injection, followed by
spleen inﬁltration and by death due to leukostasis by 14-16 days.
To our knowledge, this represents the only mouse leukemia model
in which leukemia cells home preferentially to the BM in a manner
that is similar to what is seen in human AML. AMD (5 mg/kg) at
the time of APL infusion or bid on days 0-7, had no impact on the
engraftment of either normal HSC or the PML. We observed
rapid mobilization of the APL cells when AMD was administered
11 days after APL injection. 40% of mice that received AMD on
day 11 died 2 to 4 hours after AMD injection as a result of the
rapid and massive mobilization of blasts. Interestingly, CXCR4
expression in mobilized tumor cells decreased from 33  3%
before AMD administration to 19  6%, and 7.8  0.6% after 2
and 12 hours (FACS; P .001). AMD AraC (200 mg/kg) on day
11 prolonged the overall survival of mice, compared with mice
treated only with AraC. In summary, we developed a mouse model
to study the APL cell trafﬁcking, and we have shown leukemia cell
mobilize from the BM into PB after AMD administration. In these
preliminary results we observed that AMD may sensitize APL cells
to AraC. We propose that CXCR4/SDF-1 is a key regulator for
leukemia migration and homing to the BM.
LYMPHOMA/MULTIPLE MYELOMA
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POSITIVE POSITRON EMISSION TOMOGRAPHY (PET) PRE-AUTOLO-
GOUS STEM CELL TRANSPLANT (ASCT) IN NON-HODGKIN LYMPHOMA
(NHL) DOES NOT PRECLUDE SUCCESSFUL OUTCOME
Bondly, C.C.1, Johnston, P.B.1, Lowe, V.J.2, Ansell, S.M.1,
Inwards, D.J.1, Porrata, L.F.1, Micallef, I.N.1 1Mayo Clinic College of
Medicine, Department of Internal Medicine, Division of Hematology/
Blood & Marrow Transplantation, Rochester, MN; 2Mayo Clinic College
of Medicine, Department of Radiology, Division of Nuclear Medicine,
Rochester, MN.
PET has become an important imaging modality for lymphoma,
and has been reported to be of prognostic signiﬁcance prior to
ASCT for NHL.Methods: To assess the prognostic value of PET
prior to ASCT in NHL, PET pre and post ASCT was prospec-
tively obtained in all NHL patients. From May 2003 to December
2004, 100 patients underwent ASCT for NHL. PET was consid-
ered positive if it had abnormal FDG uptake; CT was positive if it
had areas of lymphadenopathy as deﬁned by the international
response criteria. Results: Median age was 58 (range 17-74); 69%
were male. Patients had received a median of 2 prior chemotherapy
regimens (range 1-9). At relapse, prior to ASCT, the median IPI
was 2 (range 1-5); 31% of patients were stage I or II; 69% were
stage III or IV. Histology included DLBCL 50, transformed NHL
15, mantle cell NHL 11, low-grade NHL 8, T-cell NHL 6,
primary CNS NHL 5, and high grade NHL 5. At ASCT, 43
patients were in CR, 49 in PR, 3 in untreated relapse, and 5 had
resistant disease. The conditioning regimen was BEAM in 89;
Zevalin/BEAM in 10. Pre-ASCT PET was not obtained in 8
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patients. In the remaining 92, pre-ASCT PET was positive in 44
and negative in 48. Median follow-up was 8.7 months (range 1-25)
for the entire group and 11.8 months (range 2-25) for surviving
patients. Median remission duration for all patients was 7.1 months
(range 1-25). Patients with a positive and negative pre-ASCT PET
had an estimated 1 year OS of 61% and 77%, respectively (P 
.08). Estimated 1 year EFS was 34% and 66% in patients with
positive and negative pre-ASCT PET, respectively (P  .007). For
the 50 DLBCL patients, median follow up was 6.5 months (range
1-25) for the entire group and 10.3 months (range 2-25) for
survivors. Median EFS for the entire group 6.5 months (range
1-24). Pre-ASCT PET was obtained in 47 patients; 21 (44.6%)
were positive, 26 (55.3%) were negative. 1 year OS was 52% for
patients with a positive pre-ASCT PET and 68% for patients with
a negative pre-ASCT PET (P  .06). 1 year EFS was 40% and
52% for patients with a positive and negative pre-ASCT PET,
respectively (P  .11). Conclusion: Although a negative pre-
ASCT PET in NHL patients does predict a signiﬁcantly better
EFS and a trend toward improved OS, a substantial number of
patients with a positive PET pre-ASCT can achieve a good out-
come and do not require more aggressive therapy. In DLBCL
patients in particular, positive pre-ASCT PET did not predict a
signiﬁcantly worse OS and EFS (Table 1).
























49 61 77 .08 34 66 .007
BLBCL
(n  50)
45 52 68 .06 40 52 .11
DLBCL diffuse large B-cell lymphoma.
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NONMYELOABLATIVE UNRELATED DONOR (URD) HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) FOR THE TREATMENT OF PATIENTS
(PTS) WITH POOR-RISK, RELAPSED OR REFRACTORY MULTIPLE MY-
ELOMA
Georges, G.E.1,2, Maris, M.B.3, Maloney, D.G.1,2, Sandmaier, B.M.1,2,
Sorror, M.L.1, Shizuru, J.A.4, Niederwieser, D.W.5, Agura, E.D.6,
Bruno, B.7, McSweeney, P.A.3, Pulsipher, M.A.8, Chauncey, T.R.1,2,9,
Storer, B.E.1, Storb, R.F.1,2 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Washington, Seattle, WA; 3Rocky Moun-
tain Cancer Center, Denver, CO; 4Stanford University, Palo Alto, CA;
5University of Leipzig, Leipzig, Germany; 6Baylor University Medical
Center, Dallas, TX; 7University of Torino, Torino, Italy; 8University of
Utah, Salt Lake City, UT; 9VA Puget Sound Health Care System,
Seattle, WA.
We carried out HLA-matched URD peripheral blood stem cell
(PBSC) transplantation in 24 pts with poor-risk multiple myeloma
after nonmyeloablative conditioning with ﬂudarabine (90 mg/m2)
and 2 Gy total body irradiation. Postgrafting immunosuppression
consisted of cyclosporine and mycophenolate mofetil. The median
age of the 19 men and 5 women was 53 (range, 23-66) years.
Conventional metaphase cytogenetics obtained in 14 pts showed
13 in 6 pts and complex abnormalities in 9 pts. Stage III disease
was present in 83% and 17% had stage II disease. The median time
from diagnosis to URD HCT was 25 (range, 8-130) months, and
96% were beyond 1st complete remission (CR) or had never
achieved CR1, despite multiple lines of chemotherapy (median 4.5,
range 2-10). At study entry, 17 pts (71%) had chemotherapy-
refractory disease and 14 pts (58%) had failed prior autologous
HCT. Thirteen pts had planned autologous-URD tandem HCT,
while 11 proceeded directly to URD HCT, with the treatment
plan based on availability of autologous PBSC. The median fol-
low-up was 2.5 years after allografting. One pt experienced non-
fatal graft rejection. The incidences of acute grades II, III and
chronic graft-versus-host disease were 54%, 13% and 75%, respec-
tively. Non-relapse mortality was 22% at 2.5 years. CRs were
observed in 11 pts (46%) and partial remissions (PR) in 3 (13%).
Best disease responses were seen in pts given tandem autologous-
URD HCT with CR in 8 pts and PR in 2 pts (77% CR PR rate).
The estimated overall survival (OS) at 2.5 years for all 24 pts was
65% and progression-free survival (PFS) 41%. Pts receiving tan-
dem autologous-URD HCT had superior OS and PFS, 76% and
63%, compared to pts proceeding directly to URD HCT, 52% and
14%, respectively (PFS P value  .03). Risk factors for worse OS
included pts with signiﬁcant medical comorbidities (P  .03),
chemotherapy-refractory disease prior to HCT (P  .03), and pts
who had failed autologous HCT (P  .07). Pts who failed prior
autologous HCT had 48% OS and 30% PFS at 2.5 years. For pts
with poor-risk, relapsed or refractory multiple myeloma, cytore-
ductive autologous HCT followed with nonmyeloablative condi-
tioning and URD HCT is very promising treatment with low
non-relapse mortality, high complete remission rates and pro-
longed PFS. The results also suggest that URD HCT may provide
improved graft-versus-myeloma effect compared with HLA-
matched sibling HCT without an increase in the risk of non-
relapse mortality.
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REDUCED-INTENSITY ALLOGENEIC HEMOPOIETIC STEM CELL TRANS-
PLANTATION INDUCES DURABLE RESPONSES IN PATIENTS WITH
CHRONIC B-LYMPHOPROLIFERATIVE DISORDERS
Hertzberg, M.S.1, Bradstock, K.F.1, Szer, J.2, Gottlieb, D.1,
Roberts, A.2, Hoyt, R.2, Huang, G.1, Grigg, A.2 1BMT Service, West-
mead Hospital, Westmead, NSW, Australia; 2BMT Service, Royal
Melbourne Hospital, Melbourne, Victoria, Australia.
Thirty-six patients with chronic B-lymphoproliferative disorders
underwent reduced-intensity allogeneic stem cell transplantation
from 1999 to 2004. Diagnoses included relapsed or refractory
follicular lymphoma (FL) (n  17), mantle cell lymphoma (MCL)
(n  9), small lymphocytic lymphoma (SLL) (n  2), and chronic
lymphocytic leukaemia (CLL) (n  8). The median age at trans-
plant was 51 yrs (range, 30-66 years), time from diagnosis to
transplant was 6 years (range, 0.7 to 9.5 years), and number of prior
treatment regimens was 3 (range, 2 to 6). At the time of transplant
28% of patients were in CR, 36% were in PR, and 36% were
chemorefractory. Thirty-ﬁve patients received peripheral blood
stem cells from an HLA-identical sibling, and one from another
HLA-identical relative. Median number of CD34 stem cells in-
fused was 5.0 106 per kg (range, 0.9-18.9). Conditioning therapy
consisted of ﬂudarabine (125-150 mg/m2) and either cyclophosph-
amide (60-120 mg/kg) (n  27) or melphalan (120-140 mg/m2)
(n  9). Prophylaxis of graft versus host disease (GVHD) included
cyclosporin (CsA) and methotrexate (n  22), CsA and mycophe-
nolate mofetil (n  12), or CsA alone (n  2). Median time to
achievement of an absolute neutrophil count of 	 0.5  109/L and
a platelet count of	 20 109/L was 14 days (range, 8-22 days) and
14 days (range, 8-30 days), respectively. One patient with CLL
failed to engraft despite two donor lymphocyte infusions. Seven
patients died of causes not related to relapse including severe acute
GVHD (n  3), infection, either alone (n  1) or in association
with chronic GVHD (n  2), and intra-abdominal bleeding (n 
1). Treatment-related mortality was 8% at day 100, and 17% at
both one and two years. The cumulative incidence of grades II-IV
acute GVHD was 69% (95% CI, 54-85%). Among evaluable
patients, limited chronic GVHD was seen in 25% and extensive
chronic GVHD in 56%. Of the 33 patients assessable for response,
88% achieved a CR and 9% a PR while one patient had stable
disease. No patients have relapsed or had progressive disease. The
Kaplan-Meier estimate of the proportion of patients alive, and
without disease progression, at a median follow-up of 37 months
(range, 9-69 months) is 83% (95% CI, 76-89%). We conﬁrm that
reduced-intensity allogeneic transplantation in chronic B-lympho-
proliferative disorders can result in high and durable complete
response rates with limited toxicity but with a signiﬁcant incidence
of both acute and chronic GVHD.
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